Summary & Overview
HCPCS Q4163: Woundex Bioskin Skin Substitute, Per Square Centimeter
HCPCS Level II code Q4163 designates Woundex, a bioskin product billed per square centimeter as an add-on item to be reported in addition to a primary procedure. This code captures use of a biosynthetic skin substitute in advanced wound care, burn management, or soft-tissue reconstruction where the product is applied to a wound bed and charged by area. Nationally, product-based add-on codes like Q4163 matter because they affect facility and practitioner reimbursement for supply-intensive procedures and can influence coverage policy for costly biologic materials.
Key payers included in the overview are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of the code’s clinical context, typical sites of service, and what to expect in payer coverage discussions. The publication outlines benchmark topics commonly analyzed for such codes — pricing and utilization benchmarks, coding and billing considerations for add-on biologic products, and implications for claims processing — and notes where input data are not available. The summary provides a national-focused briefing useful for coding professionals, practice managers, and policy analysts seeking clarity on classification and service context for Q4163 without prescribing clinical or billing actions.
Billing Code Overview
HCPCS Level II code Q4163 represents Woundex, bioskin, billed per square centimeter as an add-on item to be listed separately in addition to a primary procedure. The service is a biosynthetic skin substitute product intended for application to wounds and soft-tissue defects.
-
Service type: Biologic skin substitute product used in wound management
-
Typical site of service: Outpatient wound care settings, hospital outpatient departments, ambulatory surgical centers, and specialty clinics providing advanced wound therapies
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient with a chronic full-thickness lower extremity wound presents to an outpatient wound care clinic for advanced biologic graft management. The wound has failed conservative care including debridement, offloading, and topical therapies. The clinician elects to use a biosynthetic skin substitute product billed with Q4163 (Woundex, bioskin, per square centimeter) as an add-on to the primary procedure. The typical workflow includes: initial assessment and wound measurement, wound bed preparation with sharp or enzymatic debridement, hemostasis, and placement of the bioskin graft per manufacturer's instructions. The graft is sized to the wound and billed per square centimeter using Q4163 in addition to the primary procedure code for graft application or debridement. Follow-up visits occur at 1–2 weeks to assess graft take, with additional dressing changes and possible secondary procedures (e.g., repeat debridement) as clinically indicated. Typical sites of service include outpatient wound care clinics, physician offices, ambulatory surgical centers, and hospital outpatient departments. Typical patient scenarios include diabetic foot ulcers, venous stasis ulcers, pressure injuries, and traumatic skin loss where biologic or biosynthetic skin substitutes are indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Procedure code — no modifier |